Yes, I see where you are coming from with that. The clinical trials should be the really expensive part and the analysis should be at a lower cost.
There will be other expenses - and general non research expenses look like they are over $200k per quarter.
BIT will still need to create more cash moving forward so, it is prudent to have a CR soon. All companies do that and BIT will have to set itself up for the immediate future. CR is not a dirty word - just a management tool
Thanks for pointing that out.
BIT Price at posting:
6.9¢ Sentiment: None Disclosure: Not Held
